Technical Analysis for GRTS - Gritstone Oncology, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.75 | -1.48% | -0.01 |
GRTS closed down 1.48 percent on Wednesday, May 15, 2024, on 46 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | -1.48% | |
| Wide Bands | Range Expansion | -1.48% | |
| Down 3 Days in a Row | Weakness | -1.48% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 16 hours ago |
| Down 2 % | about 16 hours ago |
| Down 1% | about 16 hours ago |
| Up 3% | about 19 hours ago |
| Up 2% | about 19 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient’s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to drive the patient’s immune system to attack and destroy tumors.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Oncology Tumor Cancer Immunotherapy Machine Learning Virotherapy Immunotherapies Biopsy Tumor Cell
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Oncology Tumor Cancer Immunotherapy Machine Learning Virotherapy Immunotherapies Biopsy Tumor Cell
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.33 |
| 52 Week Low | 0.6716 |
| Average Volume | 3,192,628 |
| 200-Day Moving Average | 1.83 |
| 50-Day Moving Average | 1.48 |
| 20-Day Moving Average | 0.83 |
| 10-Day Moving Average | 0.88 |
| Average True Range | 0.12 |
| RSI (14) | 32.89 |
| ADX | 32.82 |
| +DI | 15.35 |
| -DI | 28.52 |
| Chandelier Exit (Long, 3 ATRs) | 0.69 |
| Chandelier Exit (Short, 3 ATRs) | 1.02 |
| Upper Bollinger Bands | 1.02 |
| Lower Bollinger Band | 0.65 |
| Percent B (%b) | 0.27 |
| BandWidth | 44.20 |
| MACD Line | -0.15 |
| MACD Signal Line | -0.18 |
| MACD Histogram | 0.0345 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.84 | ||||
| Resistance 3 (R3) | 0.84 | 0.82 | 0.82 | ||
| Resistance 2 (R2) | 0.82 | 0.80 | 0.82 | 0.82 | |
| Resistance 1 (R1) | 0.79 | 0.78 | 0.77 | 0.78 | 0.81 |
| Pivot Point | 0.76 | 0.76 | 0.76 | 0.76 | 0.76 |
| Support 1 (S1) | 0.73 | 0.74 | 0.72 | 0.72 | 0.69 |
| Support 2 (S2) | 0.70 | 0.73 | 0.70 | 0.68 | |
| Support 3 (S3) | 0.67 | 0.70 | 0.68 | ||
| Support 4 (S4) | 0.66 |
